All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
MIBC - (neo)adjuvant (NA), anti-PD-(L)1 vs. non active control, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-010, 2021 0.85 [0.66; 1.09]
0.85 [0.66 ; 1.09 ] IMvigor-010, 2021 1 0% 809 NA not evaluable RFS/DFSdetailed results CheckMate 274 (all population), 2017 0.72 [0.59; 0.88]
CheckMate 274 (PDL1>1%), 2017 0.55 [0.39; 0.78]
0.65 [0.51 ; 0.84 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017 2 40% 991 low not evaluable DMFSdetailed results CheckMate 274 (all population), 2017 0.75 [0.59; 0.95]
CheckMate 274 (PDL1>1%), 2017 0.61 [0.42; 0.89]
0.71 [0.58 ; 0.86 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017 2 0% 991 low not evaluable events or deaths (EFS)detailed results CheckMate 274 (all population), 2017 0.70 [0.55; 0.90]
CheckMate 274 (PDL1>1%), 2017 0.55 [0.35; 0.86]
IMvigor-010, 2021 0.89 [0.74; 1.08]
0.74 [0.58 ; 0.95 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017, IMvigor-010, 2021 3 60% 1,800 low not evaluable TRAE (any grade)detailed results CheckMate 274 (all population), 2017 2.84 [2.05; 3.92]
2.84 [2.05 ; 3.92 ] CheckMate 274 (all population), 2017 1 0% 709 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.28 [0.95; 1.74]
1.28 [0.95 ; 1.74 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.49 [0.25; 8.98]
1.49 [0.25 ; 8.98 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 2.99 [0.31; 28.90]
2.99 [0.31 ; 28.90 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 2.00 [0.50; 8.06]
2.00 [0.50 ; 8.06 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Nephritis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 8.01 [0.42; 152.12]
8.01 [0.42 ; 152.12 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 5.99 [0.30; 120.06]
5.99 [0.30 ; 120.06 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results CheckMate 274 (all population), 2017 12.09 [0.67; 217.24]
12.09 [0.67 ; 217.24 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable 0.5 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-29 06:00 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 158,252,253
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563